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Abstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting
approximately 1 in 2,000 newborns. Up to 5% of NF1 patients suffer from
pseudarthrosis of a long bone (NF1‐PA). Current treatments are often unsatisfactory,
potentially leading to amputation. To gain more insight into the pathogenesis we
cultured cells from PA tissue and normal‐appearing periosteum of the affected bone
for NF1 mutation analysis. PA cells were available from 13 individuals with NF1.
Biallelic NF1 inactivation was identified in all investigated PA cells obtained during
the first surgery. Three of five cases sampled during a later intervention showed
biallelic NF1 inactivation. Also, in three individuals, we examined periosteum‐derived
cells from normal‐appearing periosteum proximal and distal to the PA. We identified
the same biallelic NF1 inactivation in the periosteal cells outside the PA region. These
results indicate that NF1 inactivation is required but not sufficient for the
development of NF1‐PA. We observed that late‐onset NF1‐PA occurs and is not
always preceded by congenital bowing. Furthermore, the failure to identify biallelic
inactivation in two of five later interventions and one reintervention with a known
somatic mutation indicates that NF1‐PA can persist after the removal of most NF1
negative cells.
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1 | INTRODUCTION
Neurofibromatosis type 1 (NF1) is an autosomal dominantly
inherited disorder affecting approximately 1 in 2,000 newborns
(MIM# 162200; Uusitalo et al., 2015). NF1 is caused by an
inactivating mutation in the NF1 gene, encoding neurofibromin, a
negative regulator of the RAS/MAPK pathway. The mutational
spectrum of NF1 is broad and mutation hotspots are not present
(Messiaen et al., 2000; van Minkelen et al., 2014). In recent years,
several clinical features of NF1, including the distinctive café‐au‐
lait macules and neurofibromas, were shown to be caused by
biallelic NF1 inactivation in a specific cell type (De Schepper
et al., 2008; Serra et al., 2000). Besides the more common clinical
features, individuals with NF1 are prone to several bone
disorders (Monroe, Dahiya, & Gutmann, 2017). Osteoporosis,
osteopenia, scoliosis, sphenoid wing dysplasia and pseudarthrosis
(PA) of the long bones are associated with NF1 (Stevenson et al.,
2013). Up to 5% of individuals with NF1 are reported to develop
a PA (Friedman & Birch, 1997; Schindeler & Little, 2008; Young,
Hyman, & North, 2002). The NF1‐related PA is often preceded by
the congenital bowing of the long bone, the subsequent fracture
is difficult to treat and leads to PA. NF1‐related PA occurs most
often in the tibia but other long bones, such as the fibula, ulna,
and radius, may also be affected (Ramelli, Slongo, Tschappeler, &
Weis, 2001; Stevenson et al., 1999). Several treatments for NF1‐
related PA are currently in use. However, regardless of the
treatment method used, union at the PA site often remains
elusive and refractures occur frequently (Horn, Steen, &
Terjesen, 2013; Vanderstappen, Lammens, Berger, & Laumen,
2015). Therefore, amputation of the affected limb is still a
potential outcome (Horn et al., 2013; Stevenson et al., 1999;
Vanderstappen et al., 2015).
PA tissue was shown to contain biallelic NF1 inactivation in
approximately 65% of the published cases (S. M. Lee et al., 2012;
Paria et al., 2014; Sakamoto et al., 2007; Sant et al., 2015; Stevenson
et al., 2006). However, some were examined using only microsatellite
marker analyses of NF1, this being suitable to detect copy number
variations within NF1 but not point mutations or small insertions and
deletions. Why no somatic NF1 mutation is detected in all NF1‐
related PA tissues examined by regular NF1 mutation analysis or
whole exome sequencing is still unknown, although the sensitivity of
the method and available tissue is of influence. The affected cell type
and the pathogenetic mechanism responsible for PA development
and persistence also remains to be discovered.
The periosteum is known to play an important role in osteogen-
esis, both during development and fracture repair (Hutmacher &
Sittinger, 2003; Park et al., 2017; Roberts, van Gastel, Carmeliet, &
Luyten, 2014). Furthermore, cultured PA cells show similar char-
acteristics to mesenchymal lineage cells derived from periosteum of
control individuals (Cho et al., 2008). Therefore we extended our
analysis beyond cells from the PA region, to cells from the normal‐
appearing proximal and distal periosteum. Our results show that the
NF1‐related PA is a complex and likely multifactorial problem in both
young and adult individuals, with biallelic NF1 inactivation involving
the periosteum beyond the PA site. We remarkably observed NF1‐
PA in previously normally appearing bones in adults.
2 | METHODS AND MATERIALS
2.1 | Editorial policies and ethical considerations
Tissues were obtained after informed consent. This study was
approved by the Ethical Committee of the University Hospitals
Leuven (study reference number: S53799).
2.2 | Cell culture
During surgery, biopsies were taken from the PA tissue, without
identifiable periosteum present. Three individuals were sampled
extensively, besides several PA biopsies normal‐appearing peri-
osteum directly proximal and distal to the PA site was sampled
using a Bistouri and tweezers. In two individuals a small
periosteum biopsy was taken at the osteotomy site, the proximal
1/3rd of the tibia, using an up bite Kerrison clamp. Since the
biopsies were small, cells were initially cultured. The tissues were
dissociated overnight at 37°C using 160 U/ml collagenase
(catalog no. C0130; Sigma, Herent, Belgium) and 0.8 U/ml dispase
(catalog no. 10241750001; Roche, Anderlecht, Belgium). PA and
periosteum‐derived cells (PDCs) were cultured in Dulbecco's
modified Eagle medium (catalog no. 41966‐029; Invitrogen, Gent,
Belgium) supplemented with 10% fetal bovine serum (catalog no.
SH 30071.03; Hyclone, Loncin, Belgium) and 1% penicillin‐
streptomycin (catalog no. 15140‐122; Invitrogen). Both PA cells
and PDCs grow adherent, are mostly bipolar, have an elongated
shape and grow in culture as fibroblast‐like cells.
2.3 | Histopathology
When available, biopsies obtained from the PA site were patholo-
gically examined. Sections of PA tissue were stained with hematox-
ylin and eosin following standard protocol. Also, immunostaining was
performed on several PA samples for CD34 (clone QBEnd10; Dako,
Leuven, Belgium), CD44 (clone DF1485; Dako), and CD45 (clone
2B11+PD7/26; Dako).
2.4 | DNA isolation
DNA was isolated from the cultured cells between cell culture
passage 3 and 7 depending on the biopsy size, and in one case
freshly frozen PA tissues, using the QIAamp DNA mini kit
(catalog no. 51304; Qiagen, Venlo, The Netherlands). The
isolation was performed according to the manufacturer's
instructions.
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2.5 | RNA isolation
RNA was isolated from puromycin‐treated cultured cells, between
cell culture passage 3 and 7 depending on the biopsy size, using the
RNeasy Mini kit (catalog no. 74104; Qiagen). The isolation was
performed according to the manufacturer's instructions. This RNA
was used for NF1 copy DNA (cDNA) mutation analysis.
2.6 | Flow cytometry and qPCR
Using flow cytometry CD34 (catalog no. 560710; BD biosciences,
Erembodegem, Belgium), CD44 (catalog no. 560531; BD biosciences),
and CD45 (catalog no. 17–9459‐42; eBioscience, San Diego, CA)
expression in cultured PA and periosteum cells was assessed. Shortly,
200,000 cells were incubated for 20min with a 1 in 100 antibody
dilution in PBS at room temperature, washed twice with PBS and
strained before measuring.
Real‐time quantitative PCR was performed on RNA using SYBR
green I (catalog no. 04707516001; Roche Diagnostics, Vilvoorde,
Belgium). RANKL expression was determined on cultured PA and
periosteum cells.
2.7 | Mutation analysis
NF1 mutation screening (LRG_214) was performed on cDNA from
cultured PA cells. These cells were puromycin‐treated, subsequently,
mRNA was extracted and used for cDNA synthesis. NF1 sequencing
was performed as described previously (Messiaen et al., 2000).
Identified mutations were confirmed on genomic DNA. Intragenic
deletions and duplications were examined using multiplex ligation‐
dependent probe amplification (catalog no. P081‐NF1 mix 1 and
P082‐NF1 mix 2; MRC‐Holland, Amsterdam, The Netherlands)
according to manufacturer's instructions. If no somatic NF1 mutation
was identified in the cultured PA cells, the HaloPlex Noonan
syndrome kit was used (made to order; Agilent, Leuven, Belgium)
according to manufacturer's instructions, since this has a lower
detection threshold than the classical method. Pathogenicity of
mutations was interpreted according to ACMG guidelines. Genomic
DNA from cultured lymphocytes or buccal swabs was used to identify
the germline mutation. If available, DNA from cultured PDCs was
sequenced to examine the presence of the previously identified
somatic NF1 mutation.
In two of the three individuals sampled extensively, deep
sequencing for the identified somatic mutation was performed on
the Illumina MiSeq platform (Illumina, Brussels, Belgium) using
250 bp paired end reading. Results were analyzed in the JSI SeqNext
software (JSI Medical Systems, Ettenheim, Germany). Using this
software the number of reads for the wildtype and mutated
nucleotide(s) was determined and correlated with the percentage
of cells carrying a somatic mutation.
Cells from one individual were subjected to SNParray since
mitotic recombination was suspected. The HumanCytoSNP‐12v2.1
array (WG‐320–2102; Illumina) was performed according to the
Infinium II Assay Multi‐Sample protocol. Results were analyzed in
GenomeStudio (Illumina).
All identified NF1 mutations were submitted to the Leiden Open
Variation Database (https://databases.lovd.nl/shared/genes/NF1).
3 | RESULTS
3.1 | Biallelic NF1 inactivation detected in cultured
PA cells
In total, PA cells of 13 individuals with NF1‐related PA were analyzed
to identify the NF1 status. The germline NF1 mutation was identified
in all individuals (Table 1). Of the identified germline mutations one
was a splice‐site, four were known pathogenic missense, one was a
nonsense and six were frameshift mutations. One individual had a
multiexon deletion (exon 2–25) causing NF1 inactivation. Two
individuals, not known to be closely related and both de novo cases,
had identical germline mutations (Table 1, individuals E and F;
c.499_502del, p.Cys167Glnfs*10).
Eight of 13 individuals were sampled during the first surgery for
NF1‐PA (primary). Five individuals were sampled during reinterven-
tion whereby PA tissue was resected (later), with one or more earlier
resections of PA tissue unavailable for analysis. In all eight individuals
with cultured primary PA cells available, we found biallelic NF1
inactivation (Table 1, individuals A to H). Of the five individuals in
whom only cultured PA cells from a later surgery were examined
(later), we identified an additional somatic NF1 inactivation in three
(Table 1, individuals I to M). One individual with biallelic NF1
inactivation detected in primary PA cells underwent two reinterven-
tions (Table 1, individual G). Only 3% of PA cells, of freshly frozen
biopsy, from the first reintervention had the previously detected
somatic NF1 mutation, detectable by deep sequencing only (Table
S1). In seven biopsies from the PA region taken during the second
reintervention, analyzed on fresh frozen biopsies, the percentage of
cells with biallelic NF1 inactivation was between 0% and 1% (Table
S2). We identified 11 somatic NF1 mutations. Of these, one was a
splice‐site, two were known pathogenic missense, four were
nonsense and three were frameshift mutations. One individual had
copy‐neutral loss of heterozygosity caused by somatic recombination
on the long arm of chromosome 17 leading to homozygosity for the
germline NF1 mutation in the PA cells (Table 1, individual F; Figure
S1). The NF1 mutations identified, both germline and somatic, are
found throughout the NF1 gene and are not concentrated in an
obvious hotspot region (Table 1).
Of the 13 individuals with NF1‐related PA examined, four were
female and nine were male (not significant binomial distribution). The
tibia was affected in 10 of 13 cases whilst the fibula (solely, without
the involvement of the tibia), ulna and radius were all affected once
in our cohort (Table 1, individuals D, E, and H). All three also showed
biallelic NF1 inactivation.
Pathological examination of the available PA samples showed
that the PA sites mostly consisted of connective tissue, with
differing degrees of cellularity and vascularity with the presence of
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small deposits of adipose‐tissue, chondrogenic tissue and some-
times mineralization. Two samples showed a few focal osteoclasts,
which were not in the vicinity of bone (Figure S2). Staining for CD
markers showed that the PA tissue did not express CD45, some
samples expressed CD34 and most had high expression of CD44,
most prominently in cell‐dense regions (Figure S3). CD34 is
expressed by hematopoietic stem cells; CD44 is involved in
cell–cell interactions, adhesion and migration and expressed by,
among others, mesenchymal stem cells and CD45 is expressed by
hematopoietic lineage cells. These results were confirmed using
flow cytometry on cultured cells (Figure S4). In addition, RANKL
expression was examined in these samples but did not illustrate a
correlation between the NF1 inactivation and RANKL expression.
There was large variability in expression between samples of the
same genotype (Figure S5).
3.2 | Late‐onset NF1‐related PA
Three individuals presented with late‐onset tibial PA with an
atypical clinical history (Table 1 individuals B [52 years], I [47
years], and K [17 years]). Individual B presented with adult‐onset
fibular PA. Upon radiographic examination, slight anterolateral
bowing of the tibia was visible with cortical thickening (Figure S6).
Treatment of the fibular PA preceded the tibia fracture and
subsequent PA. Individual I had a tibial osteotomy to correct
bowing at 35 years of age, without further problems. However, at
45 years a tibial PA developed. Individual K had anterolateral tibial
bowing since childhood, with a distal fibular PA. At 17 years a
proximal tibial fracture and subsequent PA developed (Table S3).
In all of these individuals, an additional somatic NF1 inactivation
was identified in PA cells of the tibial PA tissue (Table 1,
individuals B, I, and K).
3.3 | Biallelic NF1 inactivation in periosteal‐derived
cells outside the PA site
Three of eight individuals were sampled more extensively during
their first surgery (Figure 1; Table 1, individuals F to H). For each
individual several biopsies were taken from the PA. In addition,
the normal‐appearing periosteum directly distal and proximal to
the PA site was also sampled. If the tibia was affected periosteum
from the proximal osteotomy site was biopsied, the minimum
distance between the PA site and osteotomy site was 5.8 and
3.6 cm for individual F and G respectively. The biopsies were
cultured, RNA and DNA were extracted and genetic analysis was
performed. Between 4% and 97% of cells carry a somatic NF1
mutation in the PA tissue. This varied between individuals and
between samples of the same PA site (Table 2). For the tibiae
(Table 2, individual F and G; Tables S1 and S4) 77% and 92% of
PDCs distal to the PA site have biallelic NF1 inactivation. While
proximal to the PA only 33% and 17% of cells were affected.
Cultured periosteum samples from the proximal osteotomy site
still contained 32% and 2% of PDCs with a biallelic NF1
inactivation. For the radius sampled (Table 2, individual H) the
somatic NF1 inactivation was seen in 76% of PDCs proximal to
the PA site, while distally this was limited to 15%.
TABLE 1 NF1 mutations (pathogenic or likely pathogenic according to ACMG guidelines) in cells of pseudarthrosis tissue obtained during the
first surgery (primary; individual A to H) or reintervention (later; individual I to M). Individual G was also sampled during a reintervention
(primary+later)
NF1 Germline mutation NF1 Somatic mutation
Individual Sex Age Location Intervention DNA level Protein level DNA level Protein level
A Male 5 years Tibia Primary c.1182dup p.(Lys395*) c.245C>T p.(Ser82Phe)
B Male 53 years Tibia Primary c.2970_2971del p.Met991Aspfs*29 c.7996_7997del p.Ser2666Cysfs*5
C Male 2 years Tibia Primary c.3571dup p.(Thr1191Asnfs*4) c.4367+1G>A p.Ile1424Valfs*4a
D Male 6 years Ulna Primary c.4267A>C p.(Lys1423Gln) c.5430G>A p.Trp1810*
E Male 12 years Fibula Primary c.499_502del p.Cys167Glnfs*10 c.5399_5402dup p.(Gln1801Hisfs*41)
F Female 4 years Tibia Primary c.499_502del p.Cys167Glnfs*10 cnLOHb p.Cys167Glnfs*10




Deletion ex 2–25 c.3916C>T p.Arg1306*
H Female 8 years Radius Primary c.1466A>G p.Tyr489* c.7365T>A p.(Tyr2455*)
I Male 47 years Tibia Later c.1299T>G p.(Tyr433*) c.3827G>A p.(Arg1276Gln)
J Male 18 years Tibia Later c.1186–2A>G p.(Ile396_Gln400del)a c.1246C>T p.Arg416*
K Male 17 years Tibia Later c.2325G>T p.Glu775Asp c.4033_4034del p.(Lys1345Valfs*28)
L Female 8 years Tibia Later c.1442del p.(Pro481Leufs*17) ND ND
M Female 3 years Tibia Later c.2540T>C p.Leu847Pro ND ND
Abbreviations: cnLOH, copy neutral loss of heterozygosity; ND, not detected; NF1, neurofibromatosis type 1.
Note. Reference: LRG_214 t1 (NM_000267.3) and LRG_214 p1.
asplice site mutation.
bmore information in Figure S1.
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4 | DISCUSSION
We show that biallelic NF1 inactivation is needed for a PA to develop
because it was identified in all PA samples obtained during the first
surgery. Moreover, a detectable level of cells with biallelic NF1
inactivation, using current techniques, is not required for a PA to
persist. In PA tissue harvested during reintervention, biallelic NF1
inactivation was not detected in only two of five cases examined.
One NF1‐PA case had, besides the PA cells from the primary
surgery, two reinterventions (individual G, Table 1). In PA cells from
the primary surgery, the somatic NF1 mutation was identified, which
was also present in PDCs from normal‐appearing periosteum.
Samples from subsequent interventions were therefore tested using
deep sequencing. In PA tissue from the first reintervention (using
iliac crest grafting, whereby the PA site was cleared of fibrous tissue)
only 3% of the cells had biallelic NF1 inactivation (Table S1), while PA
tissue biopsies from the second reintervention (intramedullary TEN
nailing after the second refracture), where DNA was extracted
directly without cell culture, contained 0 to 1% of cells with the
somatic NF1 inactivation (Tables S2 and S3). Thus, the virtual
complete clearing of NF1 negative cells from the PA site is not
sufficient to promote union. This, for the first time, explains why
biallelic NF1 inactivation is not always detected in NF1‐related PA
tissue obtained at surgery subsequent to the first intervention.
Although it must be noted that cell culture might influence the exact
percentage of cells with biallelic NF1 inactivation detected (not
applicable in this case, because mutation analysis was carried out on
tissue biopsies without culture), as does bone grafting at the PA site
possibly influence the percentage of cells with biallelic NF1mutations
found (second reintervention in this case). Larger PA and periosteum
biopsies would, therefore, be preferable, since direct DNA extraction
without culture would then be possible. However, due to the young
age of most patients and the central role of periosteum in bone
repair, this would be irresponsible.
In our patient cohort, we see a slight but not significant
predominance of males in line with what was previously described in
the literature (Stevenson et al., 1999). Although tibial PA was by far the
most frequent location for an NF1‐related PA to develop in our patient
cohort, we also observed for the first time biallelic NF1 inactivation in
NF1‐PA of other long bones: ulna, fibula, and radius (x‐rays in Figure
S6). In the individual with an affected radius, cells from the normal‐
appearing periosteum showed the same somatic NF1mutation as found
in the PA cells. This indicates that NF1‐related PA in locations other
than the tibia shares the same underlying pathogenetic mechanism.
Of the 13 individuals sampled, three had late‐onset tibial PA
(Table 1, individuals B, I, and K). NF1‐related PA is reported in the
literature as a pediatric problem that occurs associated with
congenital bowing of the affected long bone. These cases, however,
prove that adults affected with NF1 can still be at risk of developing a
PA, even without clinically observable prior bowing of the involved
bone. It must, however, be noted that individuals with NF1 were
shown to have an altered lower leg geometry, even without PA
(Stevenson et al., 2009). This was however not studied in these cases.
The pathogenesis underlying late‐onset NF1‐related PA also seems
to be mediated by biallelic NF1 inactivation.
For the first time, it was shown that the somatic NF1 mutation in
NF1‐related PA cases is not confined to the PA site only, but is also
present throughout the periosteum of the affected bone. This is also the
first direct evidence that the periosteum is involved in the pathogenesis
of NF1‐related PA, which was previously hypothesized (Cho et al., 2008;
S. M. Lee et al., 2012; Sakamoto et al., 2007; Sant et al., 2015). The exact
role of the periosteal cells is still unclear. Periosteum‐grafting has been
reasonably successful in treating NF1‐PA (Thabet et al., 2008). This
indicates the importance of gaining more insight into the effect of NF1
inactivation on periosteal‐derived cells.
F IGURE 1 Schematic representation of extensive pseudarthrosis
(PA) and periosteum sampling of the tibia. During extensive
sampling, several samples from the pseudarthrosis site were taken.
The normal‐appearing periosteum directly proximal and distal to the
PA site was sampled. Also, a small periosteum biopsy was taken at
the osteotomy site (at the proximal 1/3rd of the tibia, for scientific
purposes)
TABLE 2 Percentage of cultured cells carrying a somatic NF1
inactivation detected in the samples taken from several individuals
during extensive sampling. Dashes separate the percentage of NF1














Proximal PA 7–30–94% 42% 72–78%
Middle PA NS NS 72–90%
Distal PA 34–97% 4% 61–85%
Distal periosteum 77% 92% 15%
Abbreviations: NF1, neurofibromatosis type 1; NS, not sampled; PA,
pseudarthrosis.
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The fact that biallelic NF1 inactivation can be found in normal‐
appearing periosteum throughout the affected bone suggests that
additional factors are needed for a PA to develop. For the tibia, blood
supply is lowest in the distal 1/3rd of the bone and this section is
surrounded by the least amount of muscle tissue (Menck, Bertram,
Lierse, & Wolter, 1992). In addition, mechanical stress is highest in
the distal 1/3rd of the tibia (Charnley, 1956; McFarland, 1950). These
are likely local factors aiding in the initiation and possibly
maintenance of the PA. The lack of cells with a somatic NF1
inactivation from the PA site during reinterventions suggests the
involvement of additional (local) factors for the maintenance of the
PA. These could be the same as the ones needed for PA development,
or additional factors such as microenvironment changes brought on
by the initial PA tissue and/or altered chronic inflammatory
responses. Furthermore increased numbers of osteoclasts and
increased RANKL production could increase (local) bone catabolism
(Heervä et al., 2010; Park et al., 2017; Schindeler & Little, 2008).
However, in the studied samples, osteoclast infiltration and increased
RANKL production were not detected in the PA tissue and cells,
though this might be due to the relatively small sample size available.
Currently, it is not clear which additional (local) factors are involved
in NF1‐PA initiation and maintenance and what is their exact role.
The analysis of several samples from the same PA region illustrates
the heterogeneity of this tissue. It shows that the percentage of cells
carrying a somatic NF1 mutation within the PA tissue is highly variable
and that the somatic NF1 inactivation can easily be missed due to
limited sampling of the PA tissue. The heterogeneity of the PA tissue
and the presence of biallelic NF1 inactivation in periosteum tissue
outside the PA region makes it difficult to correlate the percentage of
somatic NF1 inactivation present in the PA with the severity of the PA
and possible success of treatment. However, individual F, who had the
highest percentage of biallelic NF1 inactivated PDCs at the osteotomy
site, did have the worst clinical outcome (amputation). To gain more
insight into a possible correlation between NF1 inactive cells and the
severity of the PA it is advisable to sample more NF1‐related PA cases
and sample them more extensively.
The complex pathogenesis of NF1‐PA makes it difficult to model,
although several attempts have been made in the past. Mouse
models (partly) recapitulate the genetics behind NF1‐PA and model
delayed fracture healing (El Khassawna et al., 2012; El‐Hoss et al.,
2012; Wu et al., 2011). Spontaneous PA development does however
not occur in these models. Human NF1‐related bone stromal cells
were tested and found to have elevated ENPP1 expression (de la
Croix Ndong et al., 2014). RNA sequencing discovered a tumor‐
promoting transcriptional pattern in PA cells, however, there was a
variable degree of biallelic inactivation in the samples tested (Paria
et al., 2014). Human and mouse NF1 deficient cells examined in vitro
showed reduced osteogenic differentiation (El‐Hoss et al., 2012; D. Y.
Lee et al., 2011; Leskelä et al., 2009; Zhang et al., 2011). However,
human biallelic NF1 inactivated PA and periosteal cells have yet to be
characterized in functional studies.
In summary, the obtained results indicate that biallelic NF1
inactivation is required but not sufficient for a PA to develop.
Also, the persistence of NF1‐PA does not rely solely on the
presence of NF1 negative cells. NF1 mutations detected in PA
cells were mostly small nucleotide changes. Furthermore, we
report for the first time that NF1‐related PA can have a late
onset and does not necessarily need to be preceded by congenital
bowing. Both types of NF1‐PA are associated with biallelic NF1
inactivation. Within our patient cohort, we had a slight pre-
dominance of males and the tibia was the bone most often
affected. NF1‐related PA in other long bones (fibula, ulna, and
radius) shares the same biallelic NF1 inactivation. The somatic
NF1 mutations in periosteal‐derived cells indicate the involve-
ment of periosteum in the pathogenesis of NF1‐related PA,
although the exact mechanism is still not clear. The expressed CD
markers do point to a mesenchymal stem cell‐like lineage of the
PA cells, which is indicative of a periosteum origin. NF1
inactivation of PDCs, being an important source of stem cells
for osteoblasts during fracture repair, is likely to influence the
osteogenic differentiation of these cells. Heterozygous NF1
inactivation in osteoclasts is known to increase their number at
the PA site as well as their resorption activity (Heervä et al.,
2010; Schindeler & Little, 2008). The combination of these
factors could contribute to the persistence of PA due to the
stimulatory effect on bone catabolism. This could however not be
proven on the samples we studied, because no increase in
osteoclasts was observed. Therefore functional characterization
of human NF1 inactivated periosteal‐derived cells is essential.
The results presented here illustrate the complex pathogenesis
underlying NF1‐related PA. A better understanding of this
pathogenesis is an important step towards improved treatment
of this severe orthopedic problem.
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